A Short Note About Dr Terry Hennessey: Terry Hennessey qualified in Medicine at Oxford University where he was awarded a Doctor of Medicine for his research on antibiotic-resistant on enterobacteria (undertaken with Dr Naomi Datta at the Royal Postgraduate Medical School). Keenly aware of the need to consider the serious threat posed by drug-resistant infections, Terry joined Imperial Chemical Industries Pharmaceuticals (now part of AstraZeneca) where he initiated a wide range of in vitro and in vivo tests needed for the discovery and development of novel antibacterial agents. With his medical background, scientific excellence and natural authority Terry had a wide international network. Ever a Francophile, Terry’s team included a highly professional group of chemists at ICI’s research laboratory in Reims. Notable among Terry’s achievements at ICI was the development of chlorhexidine as ‘Corsodyl’ in dental hygiene, and the novel broad-spectrum β‑lactam meropenem (originally developed by Dainippon Sumitomo Pharma Co. Ltd.).
The Terry Hennessey Microbiology Fellowship offers a young investigator (normally under the age of 35) working in the field of infectious diseases, a travel grant of up to £1,500 to present a paper/poster at the annual ASM Microbe Meeting in the USA.
This Fellowship is open to applicants on a worldwide basis and the BSAC administers this award on behalf of the Terry Hennessey Microbiology Fellowship Trust. Applications are considered by the BSAC Grants Secretary.